China's CStone Pharma Raises $150 Million in Series A for Novel Drug Program

CStone Pharma, a Shanghai-Suzhou startup, closed a $150 million Series A round to license novel drugs. The company will seek products that address China needs, with a special emphasis in immuno-oncology along with products for cardiovascular diseases, rheumatoid arthritis, hematology and autoimmune diseases. Three China-based firms -- Oriza Seed Venture Capital, Boyu Capital, and WuXi Healthcare Ventures -- invested the capital. The company said it would use the money to accelerate multiple programs into the clinic and gain rights to innovative products, first for China and ultimately the world. Apparently, the company has already acquired products, though no details were provided. More details.... Share this with colleagues: // //